↓ Skip to main content

Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis

Overview of attention for article published in BMC Cancer, September 2015
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
61 Dimensions

Readers on

mendeley
46 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis
Published in
BMC Cancer, September 2015
DOI 10.1186/s12885-015-1617-y
Pubmed ID
Authors

Ning Ma, Hui Cheng, Baodong Qin, Renqian Zhong, Bin Wang

Abstract

The benefit of adjuvant therapy (AT) for gallbladder cancer (GBC) is unclear as evidenced by conflicting results from nonrandomized studies. Here we aimed to perform a meta-analysis to determine the impact of AT on overall survival (OS). We used data from MEDLINE, EMBASE and the Cochrane Collaboration Library and published between October 1967 and October 2014. Studies that evaluated AT compared with curative-intent surgery alone for resected GBC were included. Subgroup analyses of benefit based on node status, margins status, and American Joint Committee on Cancer (AJCC) staging were prespecified. Data were weighted and pooled using random-effect modeling. Ten retrospective studies involving 3,191 patients were analyzed. There was a nonsignificant improvement in OS with AT compared with surgery alone (hazard ratio [HR], 0.76; 95 % confidence interval [CI], 0.56-1.03). A significant improvement was observed in OS with chemotherapy (CT) compared with surgery alone (HR, 0.42; 95 % CI, 0.22-0.80) by sensitivity analysis. The greatest benefit for AT was also observed in those with R1 disease (HR, 0.33; 95 % CI, 0.19-0.59), LN-positive disease (HR, 0.71; 95 % CI, 0.63-0.81), and AJCC staging meeting or exceeding tumor Stage II (HR, 0.45; 95 % CI, 0.26-0.79), but not in those with LN-negative or R0 disease. Our results strongly support the use of CT as an AT in GBC. Moreover, patients with node positivity, margin positivity, or non-stage I disease are more likely to benefit from AT.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 46 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 15%
Student > Postgraduate 6 13%
Other 4 9%
Student > Doctoral Student 4 9%
Student > Master 4 9%
Other 8 17%
Unknown 13 28%
Readers by discipline Count As %
Medicine and Dentistry 23 50%
Biochemistry, Genetics and Molecular Biology 2 4%
Business, Management and Accounting 1 2%
Nursing and Health Professions 1 2%
Physics and Astronomy 1 2%
Other 3 7%
Unknown 15 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 September 2015.
All research outputs
#20,290,425
of 22,826,360 outputs
Outputs from BMC Cancer
#6,493
of 8,303 outputs
Outputs of similar age
#224,265
of 266,946 outputs
Outputs of similar age from BMC Cancer
#142
of 165 outputs
Altmetric has tracked 22,826,360 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,303 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,946 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 165 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.